The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002373
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: November 1998

November 2, 1999
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002373 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
A Phase I/II Trial to Evaluate the Tolerability, Anti-CMV Activity and Pharmacokinetics of 1263W94 Following Multiple Oral Administration of Escalating Doses in HIV-Infected Patients With Asymptomatic CMV Shedding

To evaluate the safety and tolerability of multiple escalating doses of 1263W94 administered orally for 28 days in HIV infected patients with asymptomatic CMV shedding. To obtain preliminary evidence of the in vivo anti CMV activity of different doses of 1263W94 in humans based on quantitative reduction of CMV load in semen and if possible in other biological fluids and to explore the dose response relationship in the anti-CMV activity of 1263W94.

HIV seropositive men stratified based on CMV titer in semen at the Pre-Screen visit (30 days prior to entry). Patients with a CMV titer >= 5000 PFU/ml and a positive result upon qualitative urine CMV culture may be eligible for entry into the main group and patients with a CMV titer < 5000 PFU/ml may be eligible for entry into the satellite group. Patients will on 1263W94 for 4 weeks. Patients will be present for clinic visits on study days 1, 7, 14, 21, and 28. They will return to the clinic for post treatment evaluations on study days 42 and 56.

Interventional
Phase 1
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
  • Cytomegalovirus Infections
  • HIV Infections
Drug: Maribavir
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
56
Not Provided
Not Provided

Inclusion Criteria

Concurrent Medication:

Allowed:

Stable, chronically administered concomitant therapy for HIV infection and opportunistic diseases if patient has been on the regimen for at least one month prior to study entry.

Patients must have:

Required of Main group:

  • Minimum CMV titer of 5000 PFU/ml in semen by quantitative CMV culture on one occasion within 30 days of entry.
  • Demonstrating positive result of qualitative CMV culture in urine on one occasion within 30 days of entry.

Required of Satellite group:

  • Must have CD4+ < 150 c/mm3 (or 10% of total lymphocytes) at screen.

Required of both groups:

  • HIV infection.
  • Life expectancy > 6 months.
  • Able to comply with protocol requirements/instructions and likely to complete all study visits and evaluations as planned.

Prior Medication:

Allowed:

Stable, chronically administered concomitant therapy for HIV infection and opportunistic diseases for at least one month prior.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

  • Active CMV disease (retinitis, colitis, encephalitis, pneumonitis, etc.).
  • Visual symptoms or signs suggestive of CMV disease (e.g., floaters, visual field defects, decreased visual acuity); Unless CMV disease is excluded via ophthalmoscopy examination.
  • Active hepatitis, obstructive hepatobiliary diseases or cirrhosis.
  • Gastrointestinal disorders which, in the judgement of the investigator, might interfere with oral dosing and drug absorption or may be indicative of CMV disease e.g., chronic nausea or vomiting, active bowel disease or persistent diarrhea.
  • Diagnosis of chronic diseases such as diabetes or hypoglycemia, epilepsy, ongoing Grade II peripheral neuropathy, congestive heart failure, cardiomyopathy, other organ dysfunctions, etc., which in the opinion of the investigator, would compromise the safety or compliance of the patient.
  • Participation in other investigational trials.
  • Patients who are so debilitated as a result of their HIV disease or associated illness or therapies such that, in the investigator's opinion, the condition may interfere with the study assessments or the patient's ability to complete the entire study per protocol requirements.

Concurrent Medication:

Excluded:

Systemic therapy for visceral malignancy.

Concurrent Treatment:

Excluded:

Treatment with radiation therapy for visceral malignancy.

Patients with any of the following prior symptoms or conditions are excluded:

  • History of CMV disease (such as retinitis, colitis, encephalitis, pneumonitis, etc.)
  • Known history of lactose intolerance.

Prior Medication:

Excluded:

  • Systemic therapy for visceral malignancy within 2 months prior to entry.
  • Prior treatment with ganciclovir, foscarnet, cidofovir, or other investigational anti-CMV drugs (e.g., intravenous acyclovir, lobucavir, valacyclovir) within 2 months prior to entry.
  • Treated with interferons, immunomodulators or CMV hyperimmune globulin within 1 month prior to entry.
  • Any investigational therapies within 1 month prior of study entry.

Prior Treatment:

Excluded:

  • Treatment with radiation therapy for visceral malignancy within 2 months prior to entry.
  • Treatment with any investigational treatments within 1 month of study entry.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002373
263A, CMAA1003
Not Provided
Not Provided
Glaxo Wellcome
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
November 1998

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP